MedTrace Logo

Testing the Effects of a Text Message Caregiver Support Intervention for Latinos

NCT06728436 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 288

Last updated 2025-12-11

No results posted yet for this study

Summary

The goal of this randomized clinical trial it to test the efficacy of CuidaTEXT, the first Alzheimer's disease and Related Dementias (ADRD) caregiver support intervention to capitalize on text messaging, among Latinos.

Researchers will compare those who receive the CuidaTEXT intervention to those who do not receive the intervention to see if CuidaTEXT effects Latino caregiver stressors and their negative consequences .

Participants will receive a variety of text messages, from automatic to keyword-drive, regarding ADRD education, social support, self-care, ADRD care management, and behavioral symptoms. Participants will also complete measures regarding depressive symptoms, coping, behavioral symptoms, and preparedness for caregiving.

Conditions

  • Alzheimer Disease

Interventions

BEHAVIORAL

CuidaTEXT

CuidaTEXT is a multidomain, bilingual 6-month text message intervention that includes delivery and content features tailored to Latino caregivers. All caregivers receive one core daily automatic message on five domains: ADRD education, social support, self-care, ADRD care management, and behavioral symptoms. Caregivers can access on-demand automatic messages to expand on the five domains via sending keywords and interact with a coach via a live chat for more personalized help.

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • University of Puerto Rico

    collaborator OTHER

  • Icahn School of Medicine at Mount Sinai

    collaborator OTHER

  • University of Miami

    collaborator OTHER

  • University of Kansas Medical Center

    lead OTHER

Principal Investigators

  • Jaime Perales Puchalt, PhD, MPH · University of Kansas Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-17
Primary Completion
2029-05-31
Completion
2029-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06728436 on ClinicalTrials.gov